NR1H4 and hepatocellular carcinoma: Pharmacological FXR activation and/or therapeutic exploitation of the enterokine FGF19 is known to attenuate not only intestinal inflammation [22,23,31,32,33], but also hepatocellular carcinoma [41,47], by decreasing circulating BA levels and modulating the BA pool size and composition to a more hydrophilic one.